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What this paper adds
What is already known on this subject? -Alpha1-antitrypsin (AAT) deficiency is among the most common genetic diseases. Homozygous carriers of the 'PiZ' variant of AAT are highly susceptible to develop liver cirrhosis due to 'gain-offunction' toxicity of the mutant protein in hepatocytes.
-Up to 10% of Caucasians carry an AAT variant but the relevance of heterozygous carriage for developing cirrhosis remains unclear.
What this study adds
-Heterozygous PiZ carriers (PiMZ) have markedly higher odds for developing liver fibrosis, especially in the setting of alcohol misuse or metabolic liver injury.
-This finding warrants appropriate testing for the PiZ variant as a part of liver workup and a more thorough clinical monitoring of PiMZ carriers.
Introduction
Cirrhosis is the end-stage of all chronic liver diseases and is the result of a scarring process that is termed liver fibrosis. Together with its detrimental sequelae, cirrhosis constitutes a major and growing cause for morbidity and mortality worldwide (1) . Therefore, a better understanding of the underlying genetic risk factors is highly relevant. Alcohol-related and non-alcohol-related liver diseases (ALD/NAFLD) are major causes of cirrhosis and liver-related mortality (2, 3) . Both diseases share the same genetic risk factors. These comprise variants in the genes of patatin-like phospholipase domain-containing protein 3 (PNPLA3), transmembrane 6 superfamily member 2 (TM6SF2), and membrane bound O-acyltransferase domain containing 7 (MBOAT7) (4, 5) . These genetic variants have been identified by genome-wide association studies that are well suited for analysis of common genetic variants. However, variants that cause monogenic disorders are often rare and the genome-wide association approach fails to uncover such less frequent variants. A potential way to circumvent this problem is to directly address the biological role of genetic variants with a proven pathogenic potential. At this point, mutations in alpha1-antitrypsin (AAT; SERPINA1 gene) are attractive candidates. AAT is one of the most abundant serum proteins and is produced predominantly within hepatocytes (6) . The presence of SERPINA1 variants typically lead to decreased serum AAT concentrations giving rise to the systemic disease alpha1-antitrypsin deficiency (AATD). Severe AATD is characterized by very low AAT serum levels (10-20% of normal), and constitutes a 'frequent rare disease' with an incidence between 1:2000 and 1:4000 (6) (7) (8) . Accordingly, severe AATD is the third most common genetic disorder leading to death worldwide (7, 9) . The lung and the liver are the organs most commonly affected and their involvement accounts for the high morbidity and mortality (7, 9) .
The nomenclature of AAT variants is based on the mobility of the resulting protein in the electric field (6, 9) . The most relevant variant is termed 'PiZ' (rs28929474) which has a prevalence of up to 8% in Northern Europe (6, 8) . The somewhat less severe variant, termed 'PiS' (rs17580), is more common in Southern Europe, with a prevalence of up to 20% (6) . In total, approximately 120 million people worldwide carry at least one PiZ or PiS allele (6, 8) . 'PiMM' describes the wild-type genotype and 'PiZZ' (i.e., the homozygous PiZ carriage) constitutes the classic severe AATD form (6, 7) . While presence of the PiZZ genotype precipitates the development of liver disease (6, 10) , the impact of heterozygous PiZ carriage (PiMZ genotype) is controversial (9) . Even less well established is the impact of heterozygous or homozygous PiS carriage (PiMS or PiSS genotype, respectively) on liver disease.
Led by the a priori hypothesis that the presence of heterozygous AAT variants may spur the liver disease development in susceptible individuals, we evaluated the impact of heterozygous PiZ or PiS carriage in different settings. First, we studied a large cohort of heterozygous PiZ carriers. Secondly, we analysed well-described cohorts of patients with NAFLD and chronic alcohol misuse for the presence of both the PiZ and the PiS variant.
Methods

Cohort of PiMZ carriers and non-carriers
A total of 352 adult carriers and non-carriers of the PiZ variant of self-reported European descent were recruited in the period from 1 April 2015 through 31 August 2017. None of the carriers and noncarriers was known to have liver disease and the primary objective was to assess their extent of liver disease.
Carriers (n=176) were defined as individuals with heterozygous carriage of the alpha1-antitrypsin (AAT) PiZ variant ('PiMZ' genotype). While some PiMZ carriers were known to have AATD, others have been recruited from families with a known case but had not themselves been genotyped previously. Only participants with a proven PiMZ genotype regardless of the AAT serum level were included. All carriers were recruited in close collaboration with the German, Belgian, Dutch, and Austrian patient advocacy groups as well as with respiratory physicians with a specialist interest in AATD. This awareness campaign was spear-headed by the University Hospital Aachen which is the coordinating center for AATD-related liver disease in two European initiatives (The European Association for the Study of the Liver (EASL) registry group 'Alpha1-Liver' and The European Reference Network (ERN) 'Rare-Liver') and was supported via an AATD liver-related homepage, telephone hotline, a presence on social media, as well as contributions to patient-centered periodicals. Individuals listed in the German national AATD registry were also offered a participation in the program.
Non-carriers (n=176) had no evidence of any AAT mutation ('PiMM' genotype or wild-type). They had been recruited as spouses of patients with known AATD or as participants in a 'liver awareness campaign' organized by the University Hospital Aachen, Germany which provided a 'liver check-up' for the general population.
The inclusion criteria were a valid assessment via transient elastography (TE; FibroScan, Echosens, Paris, France) of the liver and an ability to provide written informed consent. Main exclusion criteria were age <18 years and pregnancy. Study inclusion was offered at various sites and all comers have been examined. All examinations (questionnaires, clinical examination, blood sampling, and TE) were performed within the same day. Every participant filled out detailed, standardized questionnaires including information on demographic parameters, relevant comorbidities, alcohol consumption, etc. In all participants, the presence of a previously diagnosed liver disease has been excluded by personal interview (e.g., no established diagnosis of chronic liver disease and no history of liver resection or liver transplantation) and clinical examination. Moreover, in both carriers and non-carriers, a comprehensive laboratory workup was performed using routine assays approved for use in clinical routine. Chronic infection with hepatitis B and C was excluded serologically in all subjects. Serum levels of ferritin and transferrin saturation were determined to assess for the presence of hereditary hemochromatosis and individuals with an otherwise unexplained elevation of ferritin and transferrin saturation were excluded (1 PiMZ carrier, 1 PiMM non-carrier). Patients with self-reported excess alcohol consumption (>40g/d women, >60g/d men) were excluded (1 PiMZ carrier, 1 PiMM non-carrier). Finally, patients with elevated serum alanine transaminase (ALT) or aspartate transaminase (AST) activity >5x of the sex-specific upper limit of normal (ULN) or serum alkaline phosphatase (ALP) >2x of sex-specific ULN at time of recruitment were excluded (1 PiMZ carrier and no PiMM non-carrier) since marked elevation of these values preclude a reliable measurement of liver stiffness by TE. TE is the best established method for non-invasive assessment of liver fibrosis (11, 12) and was performed according to published recommendations (e.g., exclusion of confounders such as non-fasting or the presence of hepatic inflammation) (12) . Previously suggested cut-offs for liver stiffness measurements were used (12) . All measurements had been carried out by experienced physicians and only subjects with at least ten successful measurements and an interquartile range ≤30% of median liver stiffness were evaluated. All participants provided a written informed consent and were treated according to Ethical guidelines of the 1975 Declaration of Helsinki. The study was approved by the Internal Review Board of the participating centers and was registered on ClinicalTrials.gov (NCT02929940).
Cohort of NAFLD subjects
A total of 643 cases and controls of self-reported European descent were recruited from multiple sites in Germany and Austria. In all subjects, presence of non-alcoholic fatty liver disease (NAFLD) was diagnosed using liver biopsy. The presence of fibrosis was assessed according to Kleiner classification or previous use of steatosis-inducing drugs (e.g., amiodarone, methotrexate) were also excluded.
Cases (n=68) were defined as patients with biopsy-proven NAFLD-related cirrhosis (stage F4). Controls (n=362) had histological NAFLD without evidence of liver fibrosis (stage F0). In all NAFLD subjects, the relationship between fibrosis stage and the observed PiZ and PiS risk genotypes was analysed separately.
A total of 359 German subjects were recruited during routine NAFLD workup at Leipzig, Frankfurt, Homburg, Kiel, and Hamburg and 284 Austrian subjects were recruited from ~2,500 participants in the 'Salzburg Colon Cancer Prevention Initiative' study and were examined in Oberndorf and Salzburg. Liver samples were obtained percutaneously in patients undergoing liver biopsy for suspected NAFLD/NASH or intraoperatively in patients in whom an intraoperative liver biopsy was indicated on clinical grounds such as during scheduled liver resection, exclusion of liver malignancy during major oncologic surgery, or assessment of liver histology during bariatric surgery. Portions of this NAFLD cohort have been described previously (13) (14) (15) (16) (17) (18) (19) . All patients gave their written informed consent for liver biopsy and genetic testing. The study protocol was approved by the responsible local ethics committee of participating centers, and all subjects consented to inclusion in the study.
Cohort of alcohol misusers
A total of 2462 cases and controls were recruited from multiple centers. Of these, 1798 subjects were of self-reported German/Swiss descent (cases=934, controls=864) whereas 664 subjects were of self-reported British/Irish descent (cases=317, controls=347).
Cases were defined as patients with alcohol-related cirrhosis (defined histologically or based on clinical, laboratory, endoscopic and imaging criteria) on a background of past and/or present alcohol consumption of at least 60 g/d for women and 80 g/d for men for more than 10 years, after exclusion of other common causes of cirrhosis. Controls had similar alcohol exposure but no evidence of advanced liver disease (based on clinical, laboratory, endoscopic and imaging criteria, non-invasive assessment of liver fibrosis or liver histology).
German-Swiss cohort:
A total of 1798 alcohol misusers of self-reported German or Swiss descent were examined. Cases with alcohol-related cirrhosis were recruited from the gastroenterology and hepatology departments of the university hospitals in Dresden, Leipzig, Bonn, Regensburg, Erlangen, Luebeck, Homburg, and Hamburg (all in Germany) or in Bern and Lausanne (Switzerland). Controls without evident liver disease were recruited at psychiatry centers specialized in addiction medicine in Regensburg, Munich, and Mannheim (all in Germany). Past and present alcohol consumption was quantified through a face-to-face interview. All patients underwent clinical examination, standard laboratory testing, and abdominal ultrasound. Chronic infection with hepatitis B and C was excluded serologically in all subjects. Serum levels of ferritin and transferrin saturation were determined to rule out hereditary hemochromatosis, and neither clinical nor serological signs of autoimmune liver disease were present. Cases with alcohol-related cirrhosis were diagnosed on the basis of a history of alcohol dependence and histological examination of liver tissue; or compatible historical, clinical, laboratory, radiological, and endoscopic features. Controls were diagnosed on the basis of a history of alcohol dependence and the absence of significant liver injury on histology or else the absence of historical, clinical, radiological, or endoscopic features suggestive of significant liver injury either at presentation or during prolonged follow-up. Details of recruitment protocols were reported previously (20) . All patients gave written informed consent, and the study received approval from the ethics committees of all participating centers.
British-Irish cohort: 664 alcohol misusers of self-reported British or Irish descent were recruited from the Department of Hepatology at the Royal Free Hospital, London. All had a history of prolonged alcohol misuse and fulfilled DSM-IV criteria for a diagnosis of alcohol dependence. All were examined by two experienced, senior clinicians for signs of liver injury. Blood was taken at the time of presentation for standard liver function tests; serological testing was undertaken for antibodies to hepatitis A-E, cytomegalovirus, Epstein-Barr virus, herpes simplex and varicella; mitochondrial, nuclear, smooth muscle and liver kidney autoantibodies; iron, total iron binging capacity, ferritin; copper, caeruloplasmin; AAT and tissue transglutaminase. All patients underwent abdominal ultrasound and/or abdominal CT/MRI, as indicated; all underwent routine upper GI endoscopy; histological examination was undertaken, whenever possible, of liver biopsy material obtained by percutaneous, ultrasound guided or transjugular routes; or else of explant or post-mortem liver tissue. Patients were excluded if they had any other potential cause of liver injury or if they had a BMI >30 kg/m 2 or were diabetic. Patients with AAT serum levels below laboratory reference range were genotyped (UK reference laboratory in Sheffield) and they were excluded if they had the PiZZ genotype. Cases with alcohol-related cirrhosis were diagnosed on the basis of a history of alcohol dependence and histological examination of liver tissue; or compatible historical, clinical, laboratory, radiological, and endoscopic features. Controls were diagnosed on the basis of a history of alcohol dependence and the absence of liver injury on histology or else the absence of historical, clinical, radiological, or endoscopic features suggestive of significant liver injury either at presentation or during prolonged follow-up. Further details are stated elsewhere10. The study protocol was approved by the institutional review board, and all included subjects provided written informed consent.
Genotyping
All three cohorts were genotyped for the presence of the PiZ variant (rs28929474, also known as p.E342K or Glu342Lys) and the PiS variant (rs17580, also known as p.E264V or Glu288Val) of AAT. For the PiMZ carrier cohort, genomic DNA in participants without prior genotyping was genotyped by the German reference laboratory in Marburg as described before (21) . For the NAFLD and alcohol misuser cohorts, genomic DNA from all cases and controls was genotyped using TaqMan chemistry (Applied Biosystems) as described before (20) . Moreover, genotyping was performed for the PNPLA3 variant rs738409 (hcv7241), the TM6SF2 variant rs58542926 (hcv89463510), and the MBOAT7 variant rs641738 (hcv8716820). All process data was logged and administered using a database-driven LIMS (22) .
Statistical analyses
Continuous variables were displayed as mean±standard deviation (SD) and were compared by an unpaired, two-tailed t-test as well as by a multivariate linear model to account for relevant confounders.
Categorical variables were reported as absolute (n) and relative (%) frequencies and contingency tables were analysed with Chi-square test. Mantel-Haenzsel linear-by-linear test for trend was used to assess the relationship between advanced fibrosis stage and observed PiZ and PiS risk genotypes in NAFLD subjects. Associations between clinical outcome parameters (e.g., liver stiffness, presence of cirrhosis) and potential risk factors (e.g., genotype) were assessed by binary logistic regression analysis in order to calculate odds ratios (OR). ORs were given with their corresponding 95% confidence intervals [in brackets]. Multivariable logistic regression was used to test for independent associations. Nominal twosided p values were reported for all tests and were corrected for multiple testing by Bonferroni correction, wherever appropriate. Fixed-effect model meta-analysis was performed using the inverse varianceweighted method to summarise PiZ and PiS effect sizes in different cohorts. Herefore, the program META (1.6.0) was used.
Differences were considered to be statistically significant when p<0.05. Statistical analyses were performed using SPSS version 23 (IBM, Armonk, NY, USA) and the graphs were created with Microsoft Office (Microsoft, Redmond, WA, USA) and Prism 5 (GraphPad, La Jolla, CA, USA).
Patient involvement
Patients were actively involved in the recruitment of the the PiMZ carrier/non-carrier cohort (details see above). In particular, we closely collaborated with various patient interest groups and offered examinations at various sites. As an appreciation of this joint effort, Pavel Strnad was elected as a member of the scientific advisory board of the German AATD patient advocacy group. Every study participant received a comprehensive evaluation as well as recommendations for further liver care.
Additionally, study results were disseminated at AATD patient meetings in several European countries.
Results
PiMZ carriers displayed an increased liver disease burden
To assess the liver disease burden in individuals with the heterozygous 'PiMZ' genotype, we recruited a cohort of PiMZ carriers and non-carriers without known liver disease. Both groups displayed similar age, sex distribution, BMI values, and rates of diabetes mellitus (Table 1) . Relevant alcohol consumption (>12g/d for women/>24g/d for men) was infrequent in both groups (individuals with consumption of >40g/d for women/>60g/d for men were excluded upfront), but tended to be more common in non-carriers ( Table 1) . As expected, PiMZ carriers had markedly lower serum AAT concentrations compared to non-carriers (Fig. 1A) . The previously suggested cut-off AAT level of 110 mg/dL (23) discriminated well between both groups. Serum liver enzyme activities were increased above the sexadjusted upper limit of normal (ULN) in only a minority of PiMZ carriers: alanine aminotransferase (ALT):
15.4%, aspartate aminotransferase (AST): 5.1%, and gamma-glutamyltransferase (GGT): 16.6%. The mean serum ALT, AST, and GGT activities were higher in PiMZ carriers than non-carriers (76% vs. 65% of ULN, 66% vs. 61% of ULN, and 78% vs. 55% of ULN, respectively; p<0.05 for all; Fig. 1B-D) . In contrast, the cholestatic markers serum alkaline phosphatase (ALP) and serum bilirubin were not different between the groups (Fig. 1E-F) . A multivariate adjustment of serum AAT, ALT, AST, GGT, ALP, and bilirubin for the covariates sex, age, BMI, and the presence of diabetes mellitus confirmed that the associations of serum AAT, ALT, AST and GGT concentrations with the genotype were independent (p<0.05 for all). 
PiZ variant increased the risk to develop cirrhosis in NAFLD
The increased liver stiffness in PiMZ carriers prompted us to investigate the role of AAT variants as disease modifier in patients with a second hit. First, we focused on patients with non-alcoholic fatty liver disease (NAFLD). Here, we genotyped a German-Austrian cohort of 643 patients with biopsy-proven NAFLD for the presence of the PiZ and the PiS variants (Supplementary table 1 1B ).
Taken together, the presence of the PiZ variant, but not the PiS variant, constitutes a strong risk factor to develop NAFLD-related cirrhosis.
PiZ variant increased the risk to develop cirrhosis in alcohol misusers
The link between the PiZ variant and the development of liver disease in NAFLD patients prompted us to investigate the impact of the same two AAT variants, PiZ and PiS, in two wellcharacterized cohorts of alcohol misusers, which in total comprised 2462 individuals (German-Swiss cohort, Supplementary Altogether, our data indicate that carriage of the PiZ variant represents a strong factor predisposing to develop liver fibrosis, whereas the PiS variant does not confer a major risk.
Discussion
In the present study, for the first time, we prospectively evaluated liver injury and the stage of liver fibrosis in PiMZ carriers. The fact that PiMZ subjects display higher liver enzyme levels and higher liver stiffness than those without AAT mutations does suggest that PiMZ carriers either have subclinical liver disease and/or are more susceptible to develop liver disease after a second hit. In addition to our genetic association data, the increased TE values found in obese PiMZs support the second-hit theory. With regard to that, the detrimental role of obesity for liver injury in general is well established (24) . Obesity was also shown to predispose patients with severe AATD (homozygous PiZZ genotype) to advanced liver disease (25) .
To further substantiate the data from the PiMZ cohort, we took advantage of a well-defined cohort of patients with biopsy-proven NAFLD (n=643) and two large, well-characterized cohorts of alcohol misusers (n=2462). We unambiguously found that the PiZ variant is a major risk factor for ALD-and NAFLD-related cirrhosis. These findings are in line with previously published, smaller studies (26) (27) (28) (29) .
Moreover, this study is the first report that has systematically investigated the role of the PiS variant providing evidence that this variant may also pose a weak risk to develop alcoholic cirrhosis, but further studies are needed to confirm this association. These observations mesh well with the known pathogenic significance of both PiS and PiZ variants. Because PiS forms fewer polymers than PiZ, it is less retained within hepatocytes leading to a less prominent endoplasmic reticulum (ER) protein overload than PiZ(30).
Our findings demonstrate that the PiZ variant confers an approximately six times higher odd to develop both NAFLD-and ALD-associated cirrhosis. With a frequency of 2-4% in Europe the PiZ variant is relatively rare (6, 8, 9) , but shows remarkable odds posing this variant as the hitherto strongest known genetic risk factor for NAFLD-and ALD-related cirrhosis. In fact, the odds ratio for developing cirrhosis of the PiZ variant exceed the odds ratios of other, well-established genetic risk factors, such as the PNPLA3 variant rs738409, the MBOAT7 variant rs641738, and the TM6SF2 variants rs10401969/rs58542926 (20, (31) (32) (33) .
While future research needs to define the exact molecular mechanism how AAT variants predispose for NAFLD-and ALD-related liver fibrosis and what clinical modifiers are of particular importance, several factors are likely relevant. The cellular retention of mutated AAT (such as the PiZ variant) leads to a gain-of-function toxicity that is proportional to the amount of retained protein (9) .
Notably, AAT constitutes an established acute phase protein that is induced in patients suffering from liver injury (34) . Among other factors, ethanol was shown to stimulate AAT production in a human hepatoma cell line (35) , and thus, might aggravate gain-of-function toxicity in patients with AATD. Additionally, AAT mutations lower the threshold for an ER stress response (36) ; which might be particularly relevant in NAFLD and ALD as both also challenge the ER (9, 37) . Moreover, autophagy is crucial for the degradation of mutated AAT (36) and both NAFLD and ALD have been shown to impair autophagic activity in hepatocytes (38, 39) . Finally, an increased activity of neutrophil elastase, that constitutes the most established AAT substrate, has been implicated in the development of obesity and insulin resistance (40) .
This pathway might be particularly important in subjects with AAT variants that display decreased serum AAT levels (9) .
The fact that the PiZ variant constitutes a clear and strong disease modifier should prompt its assessment in the workup of liver disease. In that respect, measuring serum AAT levels represents a relatively easy and cost-efficient method to rule out severe AATD (i.e., homozygous PiZZ genotype) (23) However, detecting heterozygous individuals (e.g., PiMZ genotype) is more challenging as their AAT serum level are often within the reference range. Further research is needed to define an optimal serum AAT cut-off level, especially in the context of chronic liver disease. In summary, our study defines the PiZ variant as an obvious single nucleotide polymorphism-based risk factor to develop NAFLD-and ALDassociated cirrhosis. At the same time, our data advocate for a careful assessment of AAT serum levels in patients with chronic liver disease. They also encourage a more thorough clinical monitoring and management of individuals with heterozygous PiZ carriage. 
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